COPAN DIAGNOSTICS, INC.
4 recall(s) on record — most severe on record: Class II.
Activity by year
- Recalls (4)
Devices registered here (1)
- Equipment, Laboratory, General Purpose, Labeled Or Promoted For A Specific Medical UseProduct code LXG (opens in a new tab) · Class I · Clinical Chemistry · 21 CFR 862.2050
Recalls & enforcement
- Class IIOngoing2025-10-29Treatment reagent functionality in respiratory specimens liquification cannot be guaranteed.
- Class IIOngoing2025-05-02Swabs for specimen collection may be prone to breakage during product usage.
- Class IITerminated2021-07-09A sterility assurance level of 10-6 cannot be guaranteed due to intentional fraud and data integrity issues at the contract sterilizer, Steril Milano.
- Class IIITerminated2013-08-09The recall of the WASP (Walk Away Specimen Process) instrument was initiated because Copan Italia SpA has upgraded the software concerning the broth inoculation table feature. The upgrade has been considered necessary from the manufacturer in order to eliminate the very low risk…
Related
- All facilities operated by COPAN ITALIA Spa
- COPAN ITALIA (IT)
- Copan WASP (IT)
- COPAN Diagnostics, Inc. (CA)
- Copan Industries, Inc. (PR)
Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this facility record at FDA → (opens in a new tab)
Cite this record
RegWarden. “COPAN DIAGNOSTICS, INC. (FEI 1000521444) — FDA facility record.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/facility/1000521444-copan-diagnostics-inc/
Alerts for COPAN DIAGNOSTICS, INC.
Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.
Want a one-page facility brief?
A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.